shoondale
22 hours ago
The PMA and FDA news, since 2017, has been coming. How has that worked out? It hasn't amounted to more than a hill of bullshit. Pump and dump on suckers.
https://www.otcmarkets.com/filing/conv_pdf?id=12414685&guid=FSL-knG_sr4-dth
"We have has seen a .05 increase from 10/14 of .09 to the current .145. Do your due diligence but clearly the market is optimistic that the pps is the result of oversold and nefarious manipulation by hedge fund traders and their brokers selling to each other driving the pps down.The PMA submission and FDA news coming within 30 days."
Isn't your last $5+ play, QTMM, a delisted and bankrupted POS where shareholders lost every last penny to the scammers manipulating them?
"$5-$10+"
"FDA Selects HemoStyp ® for CtQ Pilot ProgramHenderson, Nevada – December 4, 2017 –United Health Products, Inc. (UHP) (OTC: UEEC), manufacturer and marketer of HemoStyp®, a patented hemostaticgauze for the healthcare and wound care sectors, today announced that it is proceeding with its application for HemoStyp under the FDA’s new and innovative CtQPilot Program. The FDA selected UHP’s HemoStyp as only one of nine participants for the program. UHP management has scheduled its first face-to-face meetingwith FDA experts for January 17, 2018 to provide the agency with whatever information it needs to advance the application for premarket approval (PMA).The FDA has stated that it intends to work collaboratively with pilot program participants during the review of their PMA submission to define characteristics ofthe device that are critical to product quality, and how these characteristics are controlled in design and manufacturing prior to the postmarket inspection. For pilotprogram participants, the FDA would forego conducting the standard PMA preapproval inspection, and a postmarket inspection focusing on the PMA applicant’simplementation of the critical to quality characteristics would be conducted instead.
The CtQ Pilot Program was created to identify products that have a chemical makeup of demonstrated safe interaction with the body –as evidenced by years ofprior product usage and studies-- to be approved for Class III internal surgical use. The program’s intent is to allow products that have demonstrated repeated safeinteraction to enter the market in a more efficient manner. This application will run simultaneously with the company’s prior Class II application for expandedindication. The market for 2017 internal surgical market for hemostatic products is estimated at in excess of seven billion dollars, and is expected to grow at 7.1%over the next few years, to reach more than $8.3 billion by 2022. (http://industryarc.com/Report/15189/hemostats-market.html)
Concurrent with its CtQ Pilot Program participation, UHP reaffirms that its current Class II application – Expanded Indication submission with the US FDA--continues to progress, and is in an advanced stage of review"
Zorax
5 days ago
In summary, OTCQB is generally considered a step up from OTC Pink in terms of transparency and investor protection, making it a more attractive option for investors seeking to trade in the OTC market. Nothing like promoting otcm's own sales propaganda as if it were meaningful.
Again, tiers on the otcm is absolutely meaningless as they do not vet, or cooperate with any real government agencies. The SEC does not take anything from otcm as valid. 'Tier' is a facade for otcm to charge more while the whole company is one source in reality.
Companies must be current in their reporting and undergo an annual verification and management certification process.
That certification management is referring to the SEC guidelines for the company, but otcm isn't requiring anything more than showing paperwork. The thing is, if you stop registering with the SEC, otcm will allow you to stay on qb until there's a complaint as long as you pay the higher fees. otcm is about money, not transparency.
JimmyRich
5 days ago
The **OTC Pink** and **OTCQB** markets are both tiers of the over-the-counter (OTC) market, which is a decentralized market where securities not listed on major exchanges like the NYSE or NASDAQ are traded. Here are the key differences between the two:
1. **OTC Pink (OTCPK):**
- **Disclosure Requirements:** OTC Pink has the least stringent disclosure requirements. Companies listed here may not be required to file with the SEC, and the level of information available can vary significantly.
- **Types of Companies:** This market includes a wide range of companies, from legitimate businesses to those with financial difficulties or limited information available. It is often considered the most speculative and risky tier.
- **Investor Access:** Generally accessible to all investors, but due diligence is crucial due to the lack of information.
2. **OTCQB:**
- **Disclosure Requirements:** OTCQB has more stringent requirements compared to OTC Pink. Companies must be current in their reporting and undergo an annual verification and management certification process.
- **Types of Companies:** This market is often seen as a venture market for early-stage and developing U.S. and international companies. It includes companies that are more transparent and have met certain minimum standards.
- **Investor Access:** Also accessible to all investors, but considered less risky than OTC Pink due to better disclosure and reporting standards.
In summary, OTCQB is generally considered a step up from OTC Pink in terms of transparency and investor protection, making it a more attractive option for investors seeking to trade in the OTC market.
You just can’t handle anything that is positive.. I’m happy you don’t own shares because when this all works out… you’ll be standing there shaking your head..
shoondale
1 week ago
"HISTORY OF MISCONDUCT
The 11Alive Investigators uncovered two Georgia hospitals have revoked Kolb’s hospital privileges in the past.
According to the state medical board, St. Joseph’s Hospital in Dunwoody is one of them. In 2004, the board cited her for “unprofessional conduct.” Because it’s not an action on her license, details of the violation are not open to the public.
In the deposition though, Kolb says the hospital revoked her privileges because she wanted to carry a gun to work. The doctor claims she needed a weapon for protection after people unhappy with her book tried for years to assassinate her."
"An 11Alive investigation uncovered an Atlanta plastic surgeon accused of performing multiple unneeded surgeries.
All of the procedures involve removing breast implants, which the women claim in lawsuits the same doctor told them were leaking and making them sick. Pathology reports submitted in the case show the implants were intact – not leaking. The women claim the unnecessary surgeries cost them thousands of dollars and altered their bodies forever."
https://www.11alive.com/article/news/investigations/leaking-breast-implants-at-the-center-of-lawsuits-against-atlanta-surgeon/85-515744697
"Here is there certification and is an interesting read especially on the 7.2% ownership link "
Suzanna Kolb 5% Control Person Peachtree, GA 18,000,000 Common stock 7.2%
https://www.otcmarkets.com/otcapi/company/financial-report/413878/content
What could possibly go wrong? This frikkin UEEC train wreck keeps getting better and better. Thanks for the heads up.
shoondale
1 week ago
dogooder
Re: JimmyRich post# 10142
Friday, September 02, 2022 5:27:16 PM
Post# 10143 of 14100
positive update next week confirmed
Do idiots really fall for this obvious absurd bullshit and buy the shares being dumped. Now the storyline is uplisting? ROTFLMAO!!!!!!!
dogooder
Re: None
Monday, August 01, 2022 11:31:56 AM
Post# 9993 of 14100
scam penny stock companies do not spend 10's of millions of dollars on clinical trials, destroy the leading competitors product, undeniable proof exists that it does. Achieving a class 3 fda medical device approval is no easy task, even for the largest of companies, so given the progress, as slow as it is, and yes, mistakes have been made along the way, what has been achieved so far is remarkable, so instead of being negative, give this very small company with no revenue a little credit, they could have folded this company years ago, but it is still here, and will be around until some larger pharma buys them out.
long and strong and buying everyday
dogooder
Re: A deleted message
Thursday, September 01, 2022 10:41:55 AM
Post# 10134 of 14100
finally good news
dogooder
Re: None
Thursday, October 25, 2018 9:37:37 AM
Post# 1669 of 14101
Had a feeling something was going on behind the scene, this is great news, why would anyone sell stock at this time, potential suitors, partners, ongoing human clinical trials, selling makes no sense unless you are angry or upset with the company and do not want to see them succeed.(Maxim?)
So sell if you want, this is a real product and it works better than any other, be smart, stay the course and you will be rewarded.
shoondale
1 week ago
Criminality always hits UEEC, nothing else...https://www.sec.gov/files/litigation/complaints/2022/comp25413.pdf"FIRST CLAIM FOR RELIEF
Violations of Exchange Act Section IO(b) and Rule 10b-5 Thereunder
(UHP and Beplate)
SECOND CLAIM FOR RELIEF
Violations of Exchange Act Section I0(b) and Rules IOb-S(a) and (c) Thereunder
(Schiliro)
THIRD CLAIM FOR RELIEF
Aiding and Abetting Violations of Exchange Act Section lO(b) and Rule 10b-5(b)
(Schiliro)
FOURTH CLAIM FOR RELIEF
Violations of Securities Act Section 17(a)
(All Defendants)
FIFTH CLAIM FOR RELIEF
Violations of Exchange Act Section 13(a), 13(b)(2)(A) and 13(b)(2)(B)
of the Exchange Act and Rules 12b-20, 13a-1 and 13a-13 Thereunder
(UHP)
SIXTH CLAIM FOR RELIEF
Aiding and Abetting Violations of Exchange Act Section 13(a),
13(b)(2)(A), 13(b)2)B), and Rules 12b-20, 13a-1 and 13a-13
(Beplate and Schiliro)
SEVENTH CLAIM FOR RELIEF
Violation of Section 13(b)(5) of the Exchange Act and Exchange Act Rule 13b2-1
(Beplate and Schiliro)
EIGHTH CLAIM FOR RELIEF
Violations of Exchange Act Section 13(a) and Rule 13a-14 Thereunder
(Beplate)
NINTH CLAIM FOR RELIEF
Violations of Rule 13b2-2 of the Exchange Act
(Beplate and Schiliro)
TENTH CLAIM FOR RELIEF
Violations of Sarbanes-Oxley Act Section 304(a)
(Beplate)
ELEVENTH CLAIM FOR RELIEF
Violations of Exchange Act Section 16(a) and Rule 16a-3 Thereunder
(Beplate)"
The SEC couldn't have possibly spelled it out more clearly. This isn't anything more than fraud with people posing as shareholders on the internet raving about artificially created volume while a stockbroker at Butler Capital is the supposed CEO. There exists no products or services being sold and thus no real business.
shoondale
2 weeks ago
This profound statement is proving absolutely prophetic..."The most difficult and challenging job for thom is to keep putting out the 8k, 10q's and 10K's to keep up the facade of faking being a real company."
It appears from recent statements, and a new bullish face who espouses the use of a bribery felon as company president along with fabricating and false statements in supposed scientific studies, that what will emerge is a new face who is more willing to employ tactics such as bait and switch contracts, fraud, and pump and dump schemes than Thom is willing to do at this point. They need to increase the number of bagholders, as they dump shares, in order to support sustaining the same bid price..
Level up your trading with our powerful tools and real-time insights all in one place.
Chrism0000
19 hours ago
Hot Features
Premium
